The promise of copper lowering therapy with tetrathiomolybdate in the cure of cancer and in the treatment of inflammatory disease

Journal of Trace Elements in Medicine and Biology

Volumn 28, Issue 4, 2014, Pages 372-378

  Brewer, George J ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b Cypris LLC   (United States)

Author keywords

Cancer; Copper; Inflammation; Micrometastatic; Tetrathiomolybdate

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; CERULOPLASMIN; CONNECTIVE TISSUE GROWTH FACTOR; COPPER; CYTOKINE; DOXORUBICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; PARACETAMOL; TETRATHIOMOLYBDIC ACID; TRANSFORMING GROWTH FACTOR BETA; TRIENTINE; TUMOR NECROSIS FACTOR ALPHA;

ACUTE LIVER FAILURE; ALBUMIN BLOOD LEVEL; ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER SURVIVAL; COPPER BLOOD LEVEL; COPPER INTOXICATION; COPPER TOXICITY; DRUG EFFICACY; DRUG OVERDOSE; HEART INJURY; HEART PROTECTION; HEPATITIS; HUMAN; INFLAMMATORY DISEASE; INTOXICATION; KIDNEY FIBROSIS; LIVER CIRRHOSIS; LUNG FIBROSIS; MALIGNANT NEOPLASTIC DISEASE; MICROMETASTASIS; MYOCARDITIS; NONHUMAN; OSTEOSARCOMA; PRIMARY BILIARY CIRRHOSIS; RECURRENCE FREE SURVIVAL; REVIEW; SCLERODERMA; TOXIC HEPATITIS; TREATMENT OUTCOME; WILSON DISEASE;

EID: 85028110867     PISSN: 0946672X     EISSN: 18783252     Source Type: Journal    
DOI: 10.1016/j.jtemb.2014.07.015     Document Type: Review

References (38)

1. Brewer G.J., Hedera P., Kluin K.J., Carlson M., Askari F., Dick R.B., et al. Treatment of Wilson disease with ammonium tetrathiomolybdate: III. Initial therapy in a total of 55 neurologically affected patients and follow-up with zinc therapy. Arch Neurol 2003, 60:379-385.
2. Brewer G.J., Merajver S.D. Cancer therapy with tetrathiomolybdate: antiangiogenesis by lowering body copper - a review. Integr Cancer Ther 2002, 1:327-337.
3. Brewer G.J. Recognition, diagnosis, and management of Wilson's disease. Exp Biol Med (Maywood) 2000, 223:39-46.
4. Walshe J.M. Penicillamine, a new oral therapy for Wilson's disease. Am J Med 1956, 21:487-495.
5. Walshe J.M. Treatment of Wilson's disease with trientine (triethylene tetramine) dihydrochloride. Lancet 1982, 1:643-647.
6. Brewer G.J., Dick R.D., Johnson V.D., Brunberg J.A., Kluin K.J., Fink J.K. Treatment of Wilson's disease with zinc: XV long-term follow-up studies. J Lab Clin Med 1998, 132:264-278.
7. Brewer G.J., Terry C.A., Aisen A.M., Hill G.M. Worsening of neurologic syndrome in patients with Wilson's disease with initial penicillamine therapy. Arch Neurol 1987, 44:490-493.
8. Brewer G.J., Askari F., Lorincz M.T., Carlson M., Schilsky M., Kluin K.J., et al. Treatment of Wilson disease with ammonium tetrathiomolybdate: IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease. Arch Neurol 2006, 63:521-527.
9. Brewer G.J., Askari F., Dick R.B., Sitterly J., Fink J.K., Carlson M., et al. Treatment of Wilson's disease with tetrathiomolybdate: V. Control of free copper by tetrathiomolybdate and a comparison with trientine. Transl Res 2009, 154:70-77.
10. Askari F.K., Dick R., Mao M., Brewer G.J. Tetrathiomolybdate therapy protects against concanavalin a and carbon tetrachloride hepatic damage in mice. Exp Biol Med (Maywood) 2004, 229:857-863.
11. Ma S., Hou G., Dick R., Brewer G.J. Tetrathiomolybdate protects against liver injury from acetaminophen in mice. J Appl Res Clin Exp Ther 2004, 4:419-426.
12. Hou G., Dick R., Abrams G.D., Brewer G.J. Tetrathiomolybdate protects against cardiac damage by doxorubicin in mice. J Lab Clin Med 2005, 146:299-303.
13. Brewer G.J., Dick R., Zeng C., Hou G. The use of tetrathiomolybdate in treating fibrotic, inflammatory, and autoimmune diseases, including the non-obese diabetic mouse model. J Inorg Biochem 2006, 100:927-930.
14. McCubbin M.D., Hou G., Abrams G.D., Dick R., Zhang Z., Brewer G.J. Tetrathiomolybdate is effective in a mouse model of arthritis. J Rheumatol 2006, 33:2501-2506.
15. Hou G., Abrams G.D., Dick R., Brewer G.J. Efficacy of tetrathiomolybdate in a mouse model of multiple sclerosis. Transl Res 2008, 152:239-244.
16. Brewer G.J., Dick R., Ullenbruch M.R., Jin H., Phan S.H. Inhibition of key cytokines by tetrathiomolybdate in the bleomycin model of pulmonary fibrosis. J Inorg Biochem 2004, 98:2160-2167.
17. Brewer G.J., Ullenbruch M.R., Dick R., Olivarez L., Phan S.H. Tetrathiomolybdate therapy protects against bleomycin-induced pulmonary fibrosis in mice. J Lab Clin Med 2003, 141:210-216.
18. Song M., Song Z., Barve S., Zhang J., Chen T., Liu M., et al. Tetrathiomolybdate protects against bile duct ligation-induced cholestatic liver injury and fibrosis. J Pharmacol Exp Ther 2008, 325:409-416.
19. Askari F., Innis D., Dick R.B., Hou G., Marrero J., Greenson J., et al. Treatment of primary biliary cirrhosis with tetrathiomolybdate: results of a double-blind trial. Transl Res 2010, 155:123-130.
20. Brem S.S., Zagzag D., Tsanaclis A.M., Gately S., Elkouby M.P., Brien S.E. Inhibition of angiogenesis and tumor growth in the brain. Suppression of endothelial cell turnover by penicillamine and the depletion of copper, an angiogenic cofactor. Am J Pathol 1990, 137:1121-1142.
21. Pan Q., Kleer C.G., van Golen K.L., Irani J., Bottema K.M., Bias C., et al. Copper deficiency induced by tetrathiomolybdate suppresses tumor growth and angiogenesis. Cancer Res 2002, 62:4854-4859.
22. Cox C., Merajver S.D., Yoo S., Dick R.D., Brewer G.J., Lee J.S., et al. Inhibition of the growth of squamous cell carcinoma by tetrathiomolybdate-induced copper suppression in a murine model. Arch Otolaryngol Head Neck Surg 2003, 129:781-785.
23. Cox C., Teknos T.N., Barrios M., Brewer G.J., Dick R.D., Merajver S.D. The role of copper suppression as an antiangiogenic strategy in head and neck squamous cell carcinoma. Laryngoscope 2001, 111:696-701.
24. Khan M.K., Miller M.W., Taylor J., Gill N.K., Dick R.D., Van Golen K., et al. Radiotherapy and antiangiogenic TM in lung cancer. Neoplasia 2002, 4:164-170.
25. Pan Q., Bao L.W., Kleer C.G., Brewer G.J., Merajver S.D. Antiangiogenic tetrathiomolybdate enhances the efficacy of doxorubicin against breast carcinoma. Mol Cancer Ther 2003, 2:617-622.
26. van Golen K.L., Bao L., Brewer G.J., Pienta K.J., Kamradt J.M., Livant D.L., et al. Suppression of tumor recurrence and metastasis by a combination of the PHSCN sequence and the antiangiogenic compound tetrathiomolybdate in prostate carcinoma. Neoplasia 2002, 4:373-379.
27. Kent M.S., Madewell B.R., Dank G., Dick R., Merajver S.D., Brewer G.J. An anticopper antiangiogenic approach for advanced cancer in spontaneously occurring tumors, using tetrathiomolybdate: a pilot study in a canine animal model. J Trace Elem Exp Med 2004, 17:9-20.
28. Brewer G.J., Dick R.D., Grover D.K., LeClaire V., Tseng M., Wicha M., et al. Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: phase I study. Clin Cancer Res 2000, 6:1-10.
29. Redman B.G., Esper P., Pan Q., Dunn R.L., Hussain H.K., Chenevert T., et al. Phase II trial of tetrathiomolybdate in patients with advanced kidney cancer. Clin Cancer Res 2003, 9:1666-1672.
30. Henry N.L., Dunn R., Merjaver S., Pan Q., Pienta K.J., Brewer G., et al. Phase II trial of copper depletion with tetrathiomolybdate as an antiangiogenesis strategy in patients with hormone-refractory prostate cancer. Oncology 2006, 71:168-175.
31. Gartner E.M., Griffith K.A., Pan Q., Brewer G.J., Henja G.F., Merajver S.D., et al. A pilot trial of the anti-angiogenic copper lowering agent tetrathiomolybdate in combination with irinotecan, 5-flurouracil, and leucovorin for metastatic colorectal cancer. Invest New Drugs 2009, 27:159-165.
32. Pass H.I., Brewer G.J., Dick R., Carbone M., Merajver S. A phase II trial of tetrathiomolybdate after surgery for malignant mesothelioma: final results. Ann Thorac Surg 2008, 86:383-389. discussion 90.
33. Lin J., Zahurak M., Beer T.M., Ryan C.J., Wilding G., Mathew P., et al. A non-comparative randomized phase II study of 2 doses of ATN-224, a copper/zinc superoxide dismutase inhibitor, in patients with biochemically recurrent hormone-naive prostate cancer. Urol Oncol 2013, 31:581-588.
34. Lowndes S.A., Adams A., Timms A., Fisher N., Smythe J., Watt S.M., et al. Phase I study of copper-binding agent ATN-224 in patients with advanced solid tumors. Clin Cancer Res 2008, 14:7526-7534.
35. Schneider B.J., Lee J.S., Hayman J.A., Chang A.C., Orringer M.B., Pickens A., et al. Pre-operative chemoradiation followed by post-operative adjuvant therapy with tetrathiomolybdate, a novel copper chelator, for patients with resectable esophageal cancer. Invest New Drugs 2013, 31:435-442.
36. Pan Q., Bao L.W., Merajver S.D. Tetrathiomolybdate inhibits angiogenesis and metastasis through suppression of the NFkappaB signaling cascade. Mol Cancer Res 2003, 1:701-706.
37. Juarez J.C., Betancourt O., Pirie-Shepherd S.R., Guan X., Price M.L., Shaw D.E., et al. Copper binding by tetrathiomolybdate attenuates angiogenesis and tumor cell proliferation through the inhibition of superoxide dismutase 1. Clin Cancer Res 2006, 12:4974-4982.
38. Jain S., Cohen J., Ward M.M., Kornhauser N., Chuang E., Cigler T., et al. Tetrathiomolybdate-associated copper depletion decreases circulating endothelial progenitor cells in women with breast cancer at high risk of relapse. Ann Oncol 2013, 24:1491-1498.